Want to see POM full AI Analyst Report?
Top Page
PomDoctor Ltd. Unsponsored ADR
(NASDAQ:POM)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.61
▼(-35.64% Downside)
Action:Reiterated
Date:10/13/26
The score is held down primarily by weak financial performance—widening losses, negative equity, rising debt, and sharply worsening cash burn in 2025. Technicals add pressure with a clear downtrend across major moving averages and negative MACD, while valuation offers limited support given the negative P/E and no dividend.
Positive Factors
Revenue growth
Steady revenue expansion shows that PomDoctor is growing its commercial base despite weak profitability. Continued top-line progress can provide a platform for scaling its healthcare services, improving operating leverage, and supporting investment in higher-value technology offerings.
Negative Factors
Stressed balance sheet
Persistent negative equity and rising debt materially reduce financial flexibility and increase solvency risk. This capital structure can constrain investment in growth, raise dependence on refinancing or new funding, and make the company more vulnerable if operating losses continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Steady revenue expansion shows that PomDoctor is growing its commercial base despite weak profitability. Continued top-line progress can provide a platform for scaling its healthcare services, improving operating leverage, and supporting investment in higher-value technology offerings.
Read all positive factors
PomDoctor Ltd. Unsponsored ADR (POM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.80M
Dividend YieldN/A
Average Volume (3M)29.27K
Price to Earnings (P/E)―
Beta (1Y)2.37
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees165
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,586,974
10 Day Avg. Volume48,396
30 Day Avg. Volume29,274
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-4.75
Price to Sales (P/S)5.39
P/FCF Ratio-14.43
Enterprise Value/Market Cap105.28M
Enterprise Value/Revenue18.66M
Enterprise Value/Gross Profit136.62M
Enterprise Value/Ebitda-14.83M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PomDoctor Ltd. Unsponsored ADR Business Overview & Revenue Model
Company Description
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed fo...
PomDoctor Ltd. Unsponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.07M | 399.91M | 342.56M | 304.85M | 245.22M | 215.38M |
| Gross Profit | 3.70M | 52.28M | 47.69M | 38.72M | 54.86M | 52.51M |
| EBITDA | -34.06M | -117.90M | -24.27M | -22.99M | -3.81M | -58.58M |
| Net Income | -33.62M | -212.58M | -143.36M | -145.39M | -125.51M | -188.40M |
Balance Sheet | ||||||
| Total Assets | 11.22M | 107.56M | 46.23M | 66.31M | 48.62M | 19.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.86M | 9.58M | 7.65M | 6.72M | 2.49M | 2.17M |
| Total Debt | 66.36M | 454.94M | 441.10M | 413.29M | 361.24M | 341.26M |
| Total Liabilities | 85.85M | 588.85M | 2.14B | 2.03B | 1.95B | 1.80B |
| Stockholders Equity | -69.36M | -453.97M | -2.26B | -2.12B | -1.97B | -1.85B |
Cash Flow | ||||||
| Free Cash Flow | 1.45M | -149.49M | -16.17M | -45.91M | -22.02M | -15.68M |
| Operating Cash Flow | 1.47M | -148.48M | -16.13M | -45.80M | -22.02M | -15.68M |
| Investing Cash Flow | -9.23K | -1.61M | -33.37K | -111.89K | 0.00 | -500.00K |
| Financing Cash Flow | -682.22K | 153.93M | 17.02M | 50.07M | 22.49M | 5.44M |
PomDoctor Ltd. Unsponsored ADR Technical Analysis
Negative
0.94
Price Trends
0.87
Negative
1.18
Negative
3.24
Negative
Market Momentum
-0.03
Positive
35.40
Neutral
4.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POM, the sentiment is Negative. The current price of 0.94 is above the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.87, and below the 200-day MA of 3.24, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.40 is Neutral, neither overbought nor oversold. The STOCH value of 4.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POM.
PomDoctor Ltd. Unsponsored ADR Risk Analysis
PomDoctor Ltd. Unsponsored ADR disclosed 91 risk factors in its most recent earnings report. PomDoctor Ltd. Unsponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PomDoctor Ltd. Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.80M | -1.14 | 15.65% | ― | ― | ― | |
44 Neutral | $27.32M | -0.91 | -108.76% | 9.40% | -19.67% | 34.91% | |
44 Neutral | $122.91M | -5.02 | -179.12% | ― | -16.73% | -143.95% | |
41 Neutral | $27.32M | -1.75 | 23.64% | ― | -23.90% | -45.45% |
* Healthcare Sector Average
POM
PomDoctor Ltd. Unsponsored ADR
0.62
-83.98
-99.27%
PETS
Petmed Express
1.26
-1.30
-50.78%
YI
111
3.11
-1.24
-28.51%
LFMD
LifeMD
2.55
-3.80
-59.84%
PomDoctor Ltd. Unsponsored ADR Corporate Events
Pomdoctor Faces Nasdaq Delisting After Prolonged Bid-Price Noncompliance
Oct 9, 2026
Pomdoctor Limited disclosed that on October 6, 2026 it received a Nasdaq staff determination letter stating its American depositary shares had closed below $1.00 for 30 consecutive trading days from August 24 to October 5, 2026, breaching Nasdaq&#...
PomDoctor Shareholders Back ADR Exit and 10-for-1 Share Consolidation
Oct 2, 2026
On September 30, 2026, PomDoctor Limited held an extraordinary general meeting in Guangzhou to consider changes to its U.S. market listing structure and share capital. Shareholders representing 53,070,520 votes were present or represented by proxy...
Pomdoctor Advances AI Chronic Disease Platform and Real-World Data Commercialization
Sep 30, 2026
On September 30, 2026, Pomdoctor Limited announced further progress in its AI-enabled chronic disease management ecosystem, highlighting multiple rounds of optimization of its proprietary system using multidimensional real-world healthcare data. T...
PomDoctor Files Mid‑Year 2026 Unaudited Results with U.S. SEC
Sep 29, 2026
PomDoctor Limited has filed a Form 6‑K with the U.S. Securities and Exchange Commission dated September 29, 2026, furnishing unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025 and 2026. The s...
Pomdoctor Showcases Integrated ‘Hardware + AI + Payment’ Model to Redefine Digital Healthcare Infrastructure
Sep 24, 2026
On September 24, 2026, Pomdoctor Limited highlighted its differentiated “hardware + AI + payment” digital healthcare infrastructure model, which integrates continuous health monitoring, AI-driven analysis, physician services and embedd...
Pomdoctor to Showcase AI-Driven Healthcare Strategy at H.C. Wainwright Global Investment Conference
Sep 10, 2026
Pomdoctor Ltd., a Guangzhou-based digital healthcare company traded on Nasdaq, specializes in AI-enabled healthcare and predictive analytics, combining physician resources, wearables, artificial intelligence, payment networks and real-world data t...
PomDoctor Sets September Vote on ADR Termination and 10-for-1 Share Consolidation
Sep 4, 2026
PomDoctor Limited, a Cayman Islands-incorporated company based in Guangzhou and traded on Nasdaq as POM, operates with American depositary shares representing its Class A ordinary shares for U.S. investors. The company maintains a dual-class struc...
Pomdoctor Launches U.S. Expansion Preparations With AI-Driven Healthcare Strategy
Aug 27, 2026
Pomdoctor Limited, a digital healthcare firm focused on AI-driven predictive healthcare, operates an established platform in China that combines physician resources, wearables, payment networks and real-world data to support continuous, personaliz...
Pomdoctor Unveils AI-Powered Healthcare Intelligence Flywheel to Drive Predictive Growth
Aug 10, 2026
Pomdoctor Limited, a digital healthcare company based in Guangzhou and listed on NASDAQ, develops AI-enabled healthcare and predictive health services that integrate physician resources, wearable devices, healthcare payment networks and real-world...
Pomdoctor Unveils Four-Tier Revenue Model to Drive AI-Enabled Healthcare Growth
Aug 3, 2026
On August 3, 2026, Pomdoctor Limited outlined a four-tier diversified revenue structure designed to anchor its established B2C internet hospital and pharmaceutical supply chain operations while scaling technology-driven services. The company repor...
Pomdoctor Limited Restores Nasdaq Bid-Price Compliance, Avoids Delisting Risk
Jul 13, 2026
On July 10, 2026, Pomdoctor Limited received confirmation from Nasdaq that it had regained compliance with the exchange’s minimum bid price rule of $1.00 per share. This followed a prior January 29, 2026 notice that its American Depositary S...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.